Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903529 | 0.90 | ALDH1A1 (0.46) | ATMSMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL12864199 | 0.89 | KDM4E (0.48) | KMT2ADAOCYP1A2ALDH1A1PDGFRB | |
| SCHEMBL1170846 | 0.88 | ALDH1A1 (0.44) | ATMSMN1; SMN2L3MBTL1DAOGAA | |
| SCHEMBL1171164 | 0.88 | KMT2A (0.48) | ATMSMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL1171082 | 0.82 | RAB9A (0.51) | SMN1; SMN2LMNADAOGAAALDH1A1 | |
| SCHEMBL1171173 | 0.82 | DAO (0.63) | ATMSMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL12864229 | 0.80 | DAO (0.43) | KMT2ADAOCYP1A2ALDH1A1PDGFRB | |
| SCHEMBL12864231 | 0.79 | DAO (0.42) | DAO | |
| SCHEMBL1170929 | 0.79 | DAO (0.58) | ATMSMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL1171073 | 0.78 | DAO (0.43) | SMN1; SMN2KMT2ADAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2011017634-A2 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACORE INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017634-A2 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACORE INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010017418-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017418-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | ATM 1124/4885SMN1; SMN2 1880/4885L3MBTL1 2568/4885 |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | ATM 1124/4885SMN1; SMN2 1880/4885L3MBTL1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.